SOME COMPLEX (MAYBE NOT SO COMPLEX) THYROID CASES

m.C. 3

Pui-Ling Chan

Endocrinologist

Greenlane Medical Specialists

18th September 2019

CASE ONE – MR SA, 33 INDIAN

Complex comorbidity:

- Asthma with mild airflow obstruction, gas trapping
- Mild OSA
- Dysfunctional breathing
- Lumbar spine stenosis
- Chronic tachycardia since 2017 (normal ECHO Dec 2017)
- GORD

- Medications at initial clinic appt
- Bisoprolol
- QVAR inhaler
- Symbicort 200/6 inhaler
- Ventolin inhaler
- Father has hypothyrodidism
- Thyroid US (May 19): solid small
 hypoechoic nodules, increased gland
 vascularity

TIMELINE – MR A

- ✤ ICU admission in Feb 2019 after respiratory arrest, short intubation & ventilation
- ✤ 7/2/19: T4 22, TSH 0.10 (new)
- ✤ 11/4/19: T4 29, TSH <0.01, T3 12</p>
- ✤ Carbimazole 5mg BD started on 26/4/19
- ◆ 9/5/19: T4 39, T3 15 (Carbimazole increased to 10mg BD)
- ✤ 22/5/19: T4 35, T3 14.3 (Carbimazole increased to 15mg BD)
- ✤ Endocrine clinic on 28/5/19: Bisoprolol stop → Diltiazem CD 120mg daily started
- ◆ 28/5/19: T4 40, T3 15 (Carbimazole stayed at 15mg BD)
- ✤ 5/6/19: T4 29, T3 12 (Carbimazole 10mg BD continued), Diltiazem 180mg
- Positive TSH receptor antibody : Graves' disease

TIMELINE - GRAVES DISEASE

- Persistent tachycardia, palpitation, hand tremor persisted
- ✤ Weight stable, no dysthyroid eye disease
- ✤ 19/6/19: T4 37 (was 29), T3 10.3 (was 12) (CBZ 15mg BD, Diltiazem ^{240mg})
- ◆ 3/7/19: T4 38, T3 11.7, GGT 160, ALP 168, ALT normal
- ✤ 18/7/19: T4 47, T3 16.6
- ◆ 31/7/19: T4 45, T3 19.5 (CBZ ↑20mg BD)
- ✤ 14/8/19: T4 53, T3 22.9, GGT 242, ALP 166

MR A'S PROBLEMS

✤ T4 and T3 continue to climb despite increment in carbimazole dose

✤ New liver derangement

6.90

Persistent tachycardia despite diltiazem increased to 240mg
 (already seen Cardiologist, no heart issue)

✤ Compliant to treatment

ISSUES

Severe Graves disease

C. 30

- Persistent symptomatic tachycardia
- ✤ Asthma beta blocker not advisable
- ✤ Risk of rate related cardiomyopathy
- What is next best management plan?

GRAVES' DISEASE - MANAGEMENT

Thionamides = methimazole, carbimazole, prophythiouracil (PTU)
Carbimazole preferred to PTU : can reverse the hyperthyroidism quicker, fewer side effects, less hepatotoxic

Small goitre & mild hyperthyroidism (T4 1.0-1.5x ULN) 5-10mg daily

Moderate to severe 10-40mg daily (divide into 2 doses if >20mg)

Fewer patients need >40mg/day

SEVERE GRAVES' DISEASE

Radioiodine – less expensive, lower complication rate

me . 3

Non pregnant (except moderate to severe orbitopathy)

➤ Usually needs pre treatment with thionamide (Except mild, well tolerated hyperthyroidism)

INFLUENCE OF RADIOIODINE ON TSH Receptor Antibody

 TRAb concentration initially rise, peaks at 3-5 months after treatment, then gradually decline

* This could explain transient initial worsening of orbitopathy

✤ TRAb may persist for many years after RAI

0.0.3

PRECIPITATING & PREDISPOSING FACTORS OF GRAVES' DISEASE

- ✤ Genetic susceptibility
- ✤ Infection (viral, hepatitis C when treated with interferon)
- Stress (negative life events)
- ✤ Gender F:M 4:1
- Smoking
- Pregnancy GD tends to improve during pregnancy (increase in regulatory T cells)
- ✤ Drugs (amiodarone, CT contrast, interferon alpha, alemtuzumab for MS)

MR A'S PROGRESS

6.90

Received radioactive iodine on 4th September, with Prednisone cover for 15 days prior to his RAI

♦ On 4/9/19 (pre RAI) – T4 59 (↑), T3 23.2 (↑), GGT 159 (↓), ALP 144
(↓)

Post RAI he was started on PTU 200mg BD (equivalent to CBZ 20mg BD)

★ TFT 13/9/19: T4 35 (↓), T3 12.7 (↓), ALP 150 (slight ↑), GGT 155 (slight ↓)

LEARNING POINTS FROM CASE 1

- Management of severe Graves' disease could be complex,
 especially with other comorbidities
- ✤ Need to monitor LFT carefully

E . 310

- ✤ Close TFT monitor is essential
- ✤ If not responding to carbimazole and continue to be symptomatic,
 refer for radioactive iodine



CASE 2: MRS N, 60 MAORI

 Referred to Thyroid clinic in May 2018

Q.C. 9

- Right sided neck lump x6
 months
- Ex-smoker
- ✤ COPD
- ✤ Cervical CIN 3
- ✤ FH of T2D

- O/E: right sided thyroid nodule2cm;
- ✤ Resting pulse 66 (regular)

One sister had thyroid cancer with spine metastases, one sister had bowel
ca, one sister had pancreatic cancer

MRS N

30

Thyroid US 1 June 2018 – multinodular goitre, right central nodule
32 x 26 x 20mm with calcifications, TIRADS 4-5

Thyroid nodule FNA 17July 2018 – Benign follicular nodule,
 Bethesda category 2

LONGSTANDING T3 TOXICOSIS

 \mathcal{C}

الروحية

	Aug 19	June 19	Jan 19	Sep 18	May 18	Jan 18
T4	16	16	16	16	18	17
Т3	6.6	6.6	6.2	6.0	6.9	6.5
TSH	<0.01	<0.01	<0.01	<0.01	<0.01	<0.01

TRAb & TPO – negative What's next?

m. C. . ?

THYROID SCINTIGRAPHY 28/8/19

 \sim

CREENS (Series 1000

Thyroid Statics

Well defined hot area involving most of the <u>right</u> thyroid lobe with minimal tracer uptake in left thyroid. Overall uptake at 20 minutes upper normal at 1.8%

nterior Marker Imag

STERNAL NOTCH

AUTONOMOUS TOXIC THYROID NODULE

Second most common cause of hyperthyroidism (after Graves' disease)

Prevalence increase with age, iodine deficiency

Q.C. 9

 Result of focal and/or diffuse hyperplasia of thyroid follicular cells whose functional capacity is independent of TSH regulation

✤ 20-80% of toxic adenoma and some nodules of MNG have somatic mutation of TSH receptor gene that confers autonomous hyperctivity

INDICATIONS FOR TREATMENT

★ All overt hyperthyroidism (\uparrow T4, \uparrow T3, \downarrow TSH) due to toxic adenoma or toxic MNG require treatment

✤ If subclinical hyperthyroidism (as in Mrs N) – decision to treat is based upon the risk for developing complications (skeletal, cardiovascular) and degree of TSH suppression

THERAPEUTIC APPROACH

- Symptom control (Beta blocker atenolol or propranolol)
- Decrease thyroid hormone synthesis
- Surgery
- Radioactive iodine
- Thionamide (pretreatment before RAI or surgery, not long term)

✤ Toxic nodules and MNG <u>rarely</u> resolve spontaneously with prolonged thionamide therapy

THERAPEUTIC APPROACH

- Symptom control (Beta blocker atenolol or propranolol)
- Decrease thyroid hormone synthesis
- Surgery
- Radioactive iodine for Mrs N
- Thionamide (pretreatment before RAI or surgery, not long term)

✤ Toxic nodules and MNG <u>rarely</u> resolve spontaneously with prolonged thionamide therapy

RADIOACTIVE IODINE (RAI)

Patients not candidate for surgery (obstructive goitre, goitre>80g, coexisting malignancy, needs rapid and definitive correction of hyperthyroidism)

- ✤ Widely used for therapy of toxic adenomas or MNGs
- ✤ Oral solution or 131-I capsule

 Induces extensive thyroid tissue damage and destruction of adenoma or autonomous foci within 6-18 weeks

♦ RAI reduces thyroid volume by \sim 35-45%

RADIOACTIVE IODINE (RAI)

Thionamide should be discontinued three days before RAI is given
TSH should be still below normal when RAI is given
Thionamide can be restarted 3-7 days after RAI, and stopped on
RAI is proven to be effective

✤ After RAI, patients require monitoring for hypothyroidism or persistent or recurrent hyperthyroidism – measure T4, T3, TSH 6-8 weeks after treatment, then at 4-8 weeks interval thereafter

LEARNING POINTS FROM CASE 2

Toxic adenoma/nodules or autonomous toxic nodules are second most common cause of hyperthyroidism/subclinical hyperthyroidism

Negative antibodies

E . 3

Older patients

 Radioactive iodine more effective than prolonged thionamide therapy

Thyroid scintigraphy is the main imaging modality



CASE 3: MRS P (29YR INDIAN)

✤ Clinic 21 Dec 2018

0.6.3

- ✤ Incongruent TFT
- ✤ Marked raised (TSH), normal to raised T4
- Left thyroidectomy then completion total thyroidectomy Nov 2010 (large benign goitre)
- Current smoker
- ✤ Gained 20kg since thyroidectomy
- On Depo Provera so amenorrhoea

CONFUSING TFT

620

Ň

.9

5

6

50

C

3

	13/12/18	16/11/18	29/9/18	May 18	Apr 18	2014- 2017
T4 (10-20)	25	27	14	58	36	
TSH (0.3-4.0)	19	26	45	6.9	11	2.5-4.9
LT4 dose	100mcg/ day	stopped				400mcg/ day

BLOOD TEST 21/12/18

- ✤ T4 38, TSH 6.9 (both raised); TRAb negative
- ✤ Testosterone 0.6 nmol/L (normal)
- ✤ Prolactin 666 (<400)</p>

0.0.3

- ✤ IGF-1 750 ng/ml (94-324) {+5.7 SD}
- ✤ ACTH <1</p>
- ✤ FSH 2, LH <1</p>
- * What's going on here?

FOLLOW UP 29/3/19


- ✤ Deepening of voice
- ✤ Facial acne flare up
- Some hair loss
- ✤ Ring gets tighter on finger
- Sore gum, ?widening of teeth
- Does not drive missing road signs

BP 94/56, oily skin
IGF-1 692 (94-324; +5.7 SD); T4 27, TSH 27

✤ MRI Pituitary not done yet!


✤ Headache

MRI PITUITARY 2/4/19



6

3



(...)

DIAGNOSIS....

620

Curro Curro

Pituitary macroadenoma

m. C. 3

- ✤ Functioning
- ✤ TSHoma
- ✤ Acromegaly

PLANS AFTER MRI PITUITARY

✤ Referred to Neurosurgeon at ADHB

C. 90

- Perimetry referral for visual field testing
- ✤ Thyroxine dose reduced to 50mcg daily (T4-27)
- \clubsuit No medical treatment started for the acromegaly at that stage

PROGRESS

Endonasal transphenoidal resection of pituitary adenoma on 15th
 July 2019 (7 months after diagnosis)

Histology: adenoma producing both TSH and GH, positive for
 P1T1 and Somatostatin receptor

◆ <u>Pre-op</u> IGF-1 852, TSH 17.2, T4 30

✤ <u>Day 2 post-op</u> IGF-1 627, TSH 0.32, T4 19

POSTOPERATIVE COURSE

✤ Rx: Hydrocortisone 20mg mane, 10mg midi; thyroxine 50ug od


- ✤ 11/8/19: T4 15, TSH 1.2, Na 139, cortisol 376, IGF-1 482 (↑)
- ✤ Constant headache, no CSF leak

✤ BP 95/30, no postural drop; normal VF, some persistent acromegalic features

- ✤ To taper hydrocortisone to drop 5mg each week
- Octreotide not to be started until a repeat IGF-1 in 3 months' time


ACROMEGALY

- ✤ Clinical syndrome results from GH excessive secretion
- ✤ Rare annual incidence 6-8 per million people
- ✤ Mean age at diagnosis 40-45 years
- ✤ Most common cause is a somatotroph (GH-secreting) pituitary adenoma (1/3 of all hormone-secreting pit adenoma)
- Onset is insidious, diagnosis often delay (mean 12 years)



ACROMEGALY DIAGNOSIS

C.



ACROMEGALY EFFECTS


Somatic & metabolic effects + local compressive symptoms

Skin thickening, enlarge jaw, enlarged hands/feet

6 9 6

✤ HTN, LVH, cardiomyopathy, insulin resistance, DM, increased risk of colon polyps/cancer, goitre, sleep apnoea, carpal tunnel syndrome

ACROMEGALY TREATMENT



LEARNING POINTS FROM CASE 3

- Index of suspicion should be raised if there is persistent incongruence in TFT (?TSHoma)
- ✤ Always test pituitary panel

E . 9

- ✤ Raised prolactin could be stalk effect
- * Acromegaly features could be subtle, diagnosis is often delayed
- Treatment of acromegaly is essential in view of its metabolic and somatic effects

